# A Clinical Study of Efficacy, Safety, Tolerability and PK of ND0612H in Subjects With Advanced Parkinson's Disease

> **NCT02577523** · PHASE2 · COMPLETED · sponsor: **NeuroDerm Ltd.** · enrollment: 38 (actual)

## Conditions studied

- Parkinson's Disease

## Interventions

- **DRUG:** ND0612 (Levodopa/Carbidopa solution)
- **DRUG:** ND0612 (Levodopa/Carbidopa solution) + morning oral IR-LD/CD

## Key facts

- **NCT ID:** NCT02577523
- **Lead sponsor:** NeuroDerm Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-29
- **Primary completion:** 2016-12-20
- **Final completion:** 2017-01-31
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2023-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02577523

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02577523, "A Clinical Study of Efficacy, Safety, Tolerability and PK of ND0612H in Subjects With Advanced Parkinson's Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02577523. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*